In last trading session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) saw 1.02 million shares changing hands with its beta currently measuring 1.82. Company’s recent per share price level of $11.31 trading at $0.25 or 2.26% at ring of the bell on the day assigns it a market valuation of $802.56M. That closing price of ZNTL’s stock is at a discount of -178.16% from its 52-week high price of $31.46 and is indicating a premium of 15.47% from its 52-week low price of $9.56. Taking a look at company’s average trading volume volume of 828.42K if we extend that period to 3-months.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Upright in the green during last session for gaining 2.26%, in the last five days ZNTL remained trading in the red while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $11.31 price level, adding 5.51% to its value on the day. Zentalis Pharmaceuticals Inc’s shares saw a change of -25.35% in year-to-date performance and have moved -3.91% in past 5-day. Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) showed a performance of -21.62% in past 30-days.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Statistics highlight that Zentalis Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -29.31% of value to its shares in past 6 months, showing an annual growth rate of 16.78% while that of industry is 12.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 28.00% in the current quarter and calculating 49.20% increase in the next quarter.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $13.12 million for the same. And 7 analysts are in estimates of company making revenue of -$ in the next quarter that will end on Jun 2024. Company posted -$ and -$ of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -50.05% during past 5 years.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
